Robotic-Assisted Lobectomy Following Induction Chemoimmunotherapy Achieves Complete Pathologic Response in Stage IIIA...

Novel therapies for clinical stage IIIA lung cancer are changing the outcomes in advanced clinical stage lung cancer. A 77-year-old female patient diagnosed with clinical T4 or stage IIIA right lower lobe adenocarcinoma with a KRAS mutation. She received neoadjuvant chemoimmunotherapy for an 8 cm tumor, which showed a moderate response on imaging. The patient underwent robotic-assisted thoracoscopic right lower lobectomy and mediastinal lymph node dissection. The final pathology showed a complete response. Novel induction chemoimmunotherapy provides an opportunity to completely eradicate cancer and provides surgical therapy for patients with advanced lung cancer.